Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer

[PR Newswire] – THOUSAND OAKS, Calif., April 25, 2016 /PRNewswire/ — Amgen (AMGN) today announced plans to participate in the World Medical Innovation Forum™ on cancer held April 25-27, 2016, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. This is the second year Amgen has participated in this event as a sponsor. Read more on this. Amgen Inc. (AMGN) , valued at $122.20B, opened at $163.15. A quick look at the market, the company’s stock traded between $162.24 and $163.74 with a trailing 52-week range being $130.09 to $181.81. Priced at 15.18x this year’s forecasted earnings, AMGN shares are relatively expensive compared to the industry’s -2.05x forward p/e ratio. And for passive income investors, the company pays shareholders $4.00 per share annually in dividends, yielding 2.45%. According to a consensus of 20 analysts, the earnings estimate of $2.60 per share would be $0.12 better than the year-ago quarter and a $0.01 sequential increase. The full-year EPS estimate is $10.83, which would be a $0.45 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.32 Billion. If reported, that would be a 5.77% increase over the year-ago quarter. More recently, Citigroup Initiated AMGN at Neutral (Feb 25, 2016). Previously, Credit Suisse Initiated AMGN at to Outperform. Investors should keep in mind is that the average price target is $181.00, which is 10.94% above where the stock opened this morning. See more in (NASDAQ:AMGN) Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – UK cost agency rejects Amgen’s virus-based cancer drug Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 2016 Second Quarter Dividend Stock Update: Amgen Inc (NASDAQ:AMGN) – Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems